NCT01077505 is a Phase 1 clinical trial of albiglutide in Diabetes Mellitus, Type 2, sponsored by GlaxoSmithKline.

Who is sponsoring NCT01077505?

NCT01077505 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT01077505?

Interventions in NCT01077505: albiglutide, Oral contraceptive (Brevicon).

What condition does NCT01077505 study?

NCT01077505 studies Diabetes Mellitus, Type 2.

Is NCT01077505 still recruiting?

NCT01077505 is currently completed. Last updated 14 June 2017.

Last reviewed 2017-06-14 · How we verify

NCT01077505

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .

Completed Phase 1 Last updated 14 June 2017

What this trial tests

Phase 1 trial testing albiglutide in Diabetes Mellitus, Type 2 in 16 participants. Completed in 24 November 2010.

Timeline

15 March 2010

Primary endpoint
24 November 2010

24 November 2010

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	other
Enrollment	16
Start date	15 March 2010
Primary completion	24 November 2010
Estimated completion	24 November 2010
Sites	1 location across United States

Drugs / interventions tested

albiglutide (ALBIGLUTIDE) — full drug profile →
Oral contraceptive (Brevicon) — full drug profile →

Conditions studied

Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

Adults 18 to 40, female only, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will be an open-label study to evaluate the effect of albiglutide on the pharmacokinetics and pharmacodynamics of a standard oral contraceptive regimen (Brevicon). The primary objective of this study is to demonstrate the lack of effect of albiglutide doses on the pharmacokinetics of norethindrone and ethinyl estradiol in healthy female subjects.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Clinical pharmacology of albiglutide, a GLP-1 receptor agonist.
Young MA, Wald JA, Matthews JE, Scott R, et al · · 2014 · cited 28× · PMID 25387217 · DOI 10.3810/pgm.2014.11.2836

Verify or expand the search:

Other trials of albiglutide

Trials testing the same drug.

NCT02787551 — Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in · Phase 3 · completed
NCT00938158 — A Study of the Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects. · Phase 1 · completed

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting

Other GlaxoSmithKline trials

Trials by the same sponsor.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01077505 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 14 June 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01077505.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing